MURFREESBORO — An
MTSU professor whose work on stemming the spread of the Zika virus pandemic has
attracted attention from pharmaceutical companies will be the guest on the next
“MTSU On the Record” radio program.
Host Gina Logue’s interview with Elliot Altman, a professor
in the Department of Biology, will air from 5:30 to 6 p.m. Monday, June 6, and
from 8 a.m. to 8:30 a.m. Sunday, June 12, on WMOT-FM (89.5 and www.wmot.org).
As of May 20, Tennessee health officials had documented
three Zika cases in the state, including one in Rutherford County. With the
Southeast’s typically hot, humid summer weather, public health experts are
concerned that the mosquito-borne virus could become more prevalent in the
United States.
Altman and Neil Bodie, a researcher based in Pasadena,
California, have joined forces to alter the NS1 protein in the mosquito-spread
virus in a way that prevents the virus from hijacking the victim’s natural
antibodies.
In the laboratory, the scientists have developed an immune
complex inhibitor they call ICI406, which has proven effective in truncating
the spread of both the Ebola virus and dengue, a flu-like virus that can cause
severe fever, aches and muscle pains.
“We have enough data on this compound that it could go into
human drug trials,” said Altman. “We now have two patents that are filed — one
on the use of ICI406 against Ebola, influenza and hepatitis, and a second for
Zika.”
However, Altman emphasizes that his work is aimed at
creating a treatment to keep Zika virus patients alive, not at creating a
vaccine to prevent people from contracting the disease.
“The problem with most viral infections is it’s really hard
to develop a preventative because the viruses mutate and change too
frequently,” said Altman. “By taking ICI406, you’ll suppress the immune
complexes from exacerbating the infection.”
Gaining approval from the U.S. Food and Drug Administration
for an investigational new drug study (IND) and the human trials by
pharmaceutical companies cumulatively could take years.
To this point, the U.S. Senate has approved $1.1 billion in
funding for Zika research, while the U.S. House has approved about $622
million, most of which was transferred from funding earmarked for Ebola
research. No compromise has been reached.
Meanwhile, the U.S. Centers for Disease Control have
documented 618 Zika cases in the 50 states and 1,114 in U.S. territories. All
of the cases in the states are associated with travel to areas where the virus
is rampant, which include most of Central and South America and some Pacific
islands.
To hear previous “MTSU On the Record” programs, go to http://bit.ly/mtsu-otr.
For more information, contact Logue at 615-898-5081 or
WMOT-FM at 615-898-2800.
No comments:
Post a Comment